Contrary to our results, lower expression levels of ADAMTS9-AS1 were observed in prostate cancer [22] and breast cancer tissues [19], which were identified as a novel prognostic biomarker for clinical application. This evidence concerns the gene ADAMTS9 and prostate carcinoma.